Featured news from NHIVNA
HIV-related news from NAM
Almost-certain case of PrEP failure due to drug resistance reported at CROI conference
Gus Cairns, 2016-02-25 22:30:00
A case report of a man in Toronto who became infected with a
multi-drug-resistant strain of HIV despite apparently very consistent adherence
to PrEP was presented at the CROI 2016 conference in Boston today.
Dr David Knox, a doctor at Toronto’s Maple Leaf Medical
clinic, said the patient was a 43-year-old gay man who had been on PrEP for two
years. He had an HIV-positive partner who was undetectable on antiretroviral
therapy, but also had casual sex contacts involving the risk of HIV exposure.
He was a regular attender at the clinic and tested for HIV
on average every three months. It was suggested to him that he start Truvada
PrEP in April 2013 and he appeared to have good adherence to it on the basis of
the frequency of pharmacy refills.
Two years later in April 2015 he started having symptoms
after a period of exposure to HIV with multiple partners. The symptoms were not
classic HIV seroconversion symptoms but involved an episode of fever with abdominal
pain severe enough for him to go for hospital investigation, where a scan
revealed an inflamed colon.
During this time he came in for his regular HIV test and
this showed he had acute HIV infection, with a negative test for HIV antibodies
but a positive test for the HIV p24 antigen, which shows up sooner. His HIV
viral load three days later was 28,000 copies/ml – rather low for acute HIV
infection and suggestive that either his PrEP had ‘blunted’ viral replication without
stopping infection, or that the highly drug-resistant virus turned out to
have paid the price for its resistance by replicating weakly.
The patient was adamant that he maintained excellent
adherence to PrEP so Dr Knox, by now concerned that he might be seeing a case
of genuine PrEP failure, ordered more tests. One was a resistance test, for all
antiretroviral drug classes, for his patient’s virus, from a sample taken a
week after his HIV diagnosis.
The other needs explanation. The patient was treated within
a cash-poor public health setting and his old blood samples had not been saved.
So there was no way to directly prove that he had drug levels consistent with
high adherence around the time of HIV exposure.
There was an indirect way, however. Dr Knox analysed a
so-called Dried Blood Spot (DBS) from the patient taken 20 days after he was diagnosed. The point of a DBS test is that it measures drug
levels inside red blood cells, rather than inside the white blood cells HIV
infects, or in blood plasma. Drug levels rise much more slowly inside red blood
cells, taking 17 days to reach half of their steady-state levels, and a full
eight weeks to reach the drug-saturated steady state completely. Drug levels also rise steadily and are less susceptible to short-term peaks and troughs. Drug levels in the patient’s DBS were actually 47% higher than
the average figure, suggesting consistent PrEP adherence for most of the
period covering his exposure to HIV. If he had only been taking the drugs since
he learned his diagnosis, the drug levels would only be 47% of the average steady
state level or 31% of their actual level in this patient.
This is an indirect way of measuring drug levels, and given
that the onset of symptoms occurred four weeks before the patient’s HIV
diagnosis and the dried blood test was taken over three weeks after, and that
the period of risk according to the patient started two weeks before the onset
of symptoms, thus leaving nine weeks for drug to accumulate, this test did not
entirely rule out the possibility that he had been off PrEP at the time he took
a risk and that this had prompted him to start taking it again, though the
patient insists this is not the case.
There was a small blood sample left over from his diagnostic
test, taken three days before the patient learned he had HIV. This
revealed high levels of tenofovir and levels of emtricitabine so high they were
above the test’s limit of quantification. However this was not a test of
long-term drug levels and again cannot completely rule out the possibility that
he had had a lapse in adherence around the time he was exposed to HIV.
The resistance test showed that the patient had HIV that had
no significant resistance to the protease inhibitor class of antiretrovirals.
He had one resistance mutation to the first generation NNRTI drug nevirapine,
and complete resistance to emtricitabine. He also had extensive resistance to the first-generation NRTI drugs like zidovudine (AZT) and stavudine
(d4T), and these mutations also confer some resistance to tenofovir. However he
did not have the so-called K65R mutation that confers high-level resistance to
tenofovir, and it was estimated that the resistance pattern he did have only
confers 1.3-fold resistance to tenofovir, meaning that drug levels 30%
higher than those needed for non-resistant virus should have been enough to prevent
infection – and he had much higher drug levels than this in the tests.
Resistance, however is a complex process and some combinations of mutations can
catalyse higher levels of resistance than they would produce alone.
Not relevant to the apparent PrEP failure, but to the spread
of drug resistance, was the fact that this patient also had two resistance
mutations to the integrase inhibitor drugs and complete resistance to the drug
Transmission of HIV with integrase inhibitor resistance is
very rare, and especially resistance to drugs other than raltegravir, the
first integrase inhibitor. The pattern of resistance observed is compatible
with the unnamed person who passed on the virus being on a failing regimen of Stribild (the two-class, four-drug combination
pill of tenofovir, emtricitabine, elvitegravir and cobicistat). Given that four
out of the five first-line HIV drug regimens recommended by the US Department
of Health and Human Services are integrase inhibitor-based, and that this drug class
is being investigated for use as PrEP, it would be of concern if more integrase
inhibitor-resistant virus started to circulate.
The patient himself was put on a potent three-class regimen of
dolutegravir, rilpivirine and boosted darunavir and became virally undetectable
only three weeks after starting it.
In conclusion, this is probably not an absolutely clinching
case – one would need drug level samples taken at the time of infection for
that. But on the balance of probabilities, with three different measures all
supporting the patient’s self-report, this is probably the first documented case
of the failure of Truvada PrEP despite
high adherence and more-than-adequate drug levels though recently two
cases on solo tenofovir were published.
It is not unexpected that there would be occasional cases of
PrEP failure; but the fact that this is the first case report among the tens of
thousands of people now taking PrEP shows that it is very rare.